Histamine dihydrochloride and interleukin-2 in patients with acute myeloid leukaemia in first complete remission.

Trial Profile

Histamine dihydrochloride and interleukin-2 in patients with acute myeloid leukaemia in first complete remission.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2012

At a glance

  • Drugs Histamine dihydrochloride (Primary) ; Interleukin-2
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 30 Mar 2012 Status changed from planning to discontinued, according to EpiCept's 2011 Form 10-K
    • 27 Jun 2011 FDA advises that the protocol be amended to include an Interleukin-2 monotherapy arm (decision pending).
    • 10 May 2011 EpiCept files protocol with the FDA, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top